The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
Grifols develops and produces essential plasma medicines and other innovative biopharmaceuticals to treat chronic, rare and, at times, life-threatening conditions. The company also provides a comprehensive portfolio of solutions in transfusion medicine while supplying biological materials for research and further manufacturing. In addition, Grifols offers hospitals, pharmacies and healthcare professionals solutions and services that deliver efficient, expert medical care.
Grifols, with more than 27,000 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.
For more information, please visit www.grifols.com